Arcellx (ACLX) Operating Income (2021 - 2025)
Arcellx's quarterly Operating Income came in at $237.5 million in Q4 2025, up 546.74% year-on-year from $36.7 million in Q4 2024, and up 484.38% quarter-over-quarter from -$61.8 million in Q3 2025.
Arcellx has reported Operating Income for 5 years, with the latest figure at $237.5 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income rose 546.74% year-over-year to $237.5 million; the trailing twelve-month figure through Dec 2025 stood at $48.1 million (up 134.93% YoY), and the FY2025 full-year result was $48.1 million, up 134.93% from the prior year.
- Operating Income for Q4 2025 stood at $237.5 million, up from -$61.8 million in the prior quarter.
- The five-year high for Operating Income was $237.5 million in Q4 2025, with the low at -$93.9 million in Q3 2022.
- Average Operating Income over 5 years is -$21.8 million, with a median of -$30.9 million recorded in 2022.
- Year-over-year, Operating Income sank 454.37% in 2024 and jumped 546.74% in 2025.
- Tracing ACLX's Operating Income over 5 years: stood at -$20.7 million in 2021, then plunged by 93.27% to -$40.0 million in 2022, then soared by 137.49% to $15.0 million in 2023, then slumped by 454.37% to -$53.2 million in 2024, then jumped by 546.74% to $237.5 million in 2025.
- The last three Operating Income figures came in at $237.5 million (Q4 2025), -$61.8 million (Q3 2025), and -$58.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 237.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 237.45 Mn |
| Sep 30, 2025 | -61.78 Mn |
| Jun 30, 2025 | -58.73 Mn |
| Mar 31, 2025 | -68.90 Mn |
| Dec 31, 2024 | -53.15 Mn |
| Sep 30, 2024 | -33.62 Mn |
| Jun 30, 2024 | -34.99 Mn |
| Mar 31, 2024 | -15.81 Mn |
| Dec 31, 2023 | 15.00 Mn |
| Sep 30, 2023 | -44.86 Mn |
| Jun 30, 2023 | -29.56 Mn |
| Mar 31, 2023 | -30.46 Mn |
| Dec 31, 2022 | -40.00 Mn |
| Sep 30, 2022 | -93.88 Mn |
| Jun 30, 2022 | -31.29 Mn |
| Mar 31, 2022 | -26.09 Mn |
| Dec 31, 2021 | -20.70 Mn |
| Sep 30, 2021 | -17.11 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |